Screening and hormonal therapy of localized prostate cancer shows major benefits on survival

Cancer Journal

Volumn 6, Issue SUPPL. 2, 2000, Pages

  Labrie, Fernand ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Combined androgen blockade (CAB); LHRH agonist; Localized disease; Prostate cancer; Prostatic specific antigen (PSA); Pure antiandrogen; Screening

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

BONE METASTASIS; CANCER INVASION; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; FOLLOW UP; HORMONAL THERAPY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0033943072     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Landis SH, Murray T, Bolden S et al. Cancer Statistics 1999. Can Cancer J Clin 1999;49:8-31.
2. Labrie F, Bélanger A, Cusan L et al. Antifertility effects of LHRH agonists in the male. J Androl 1980;1:209-228.
3. Labrie F, Dupont A, Bélanger A et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982;5:267-275.
4. Labrie F, Dupont A, Bélanger, A. Complete androgen blockade for the treatment of prostate cancer. In De Vita VT, Hellman S. Rosenberg SA (eds). Important Advances in Oncology. Philadelphia. J. B. Lippincott, 1985;193-217.
5. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
6. Denis L. EORTC 30853. Cancer 1993;71:1050-1058.
7. Bennett CL, Tosteson TD, Schmitt B et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Can Prostatic Dis 1999;2:4-8.
8. Denis L, Carnelro de Moura J, Bono A et al. Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42:119-129.
9. Janknegt RA, Abbou CC, Bartoletti R et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-83.
10. Caubet JF, Tosteson TD, Dong EW et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997;49:71-78.
11. Dijkman GA, Janknegt RA, Dereijke TM et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160-163.
12. Denis LJ, Keuppens F, Smith PH et al. Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur JUrol 1998;33:144-151.
13. Labrie F, Bélanger A, Cusan L et al. History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer 1996;3:243-278.
14. Labrie F, Cusan L, Gomez JL et al. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol Urol 1997;1:253-261.
15. Lee F, Torp-Pedersen ST, Siders DB et al. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 1989;170:609-615.
16. Labrie F, Cusan L, Gomez JL et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994;44:29-37.
17. Laverdiere J, Gomez JL, Cusan L et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Rad Oncol Biol Phys 1997;37:247-252.
18. Kolata G. Prostate cancer consensus hampered by lack of data. Science 1987;236:1626-1627.
19. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
20. Pilepich MV, Caplan R, Byhardt RW et al. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997;15:1013-1021.
21. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341:1781-1788.
22. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235-246.
23. Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38: 83-91.
24. Labrie F, Candas B, Cusan L et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-217.
25. Murphy GP, Natarajan N, Pontes JE et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982;127:928-934.
26. Schmidt JD, Mettlin, CJ, Natarajan N et al. Trends in patterns of care for prostaric cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol 1986;136:416-421.
27. Labrie F, Cusan L, Gomez JL et al. Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol, 1999;3:217-225.